<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2018</study_start_year><data_sharing_plan>IPD Sharing (as of December 2017): No</data_sharing_plan><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Neoadjuvant Therapy</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Neoadjuvant Therapy</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2261627</full_dataset_link><study_start_month>1</study_start_month><keyword>Apatinib</keyword><keyword>Oxaliplatin</keyword><keyword>Leucovorin</keyword><keyword>Fluorouracil</keyword><repository>ECRIN MDR</repository><study_status>Not provided</study_status></additional><is_claimable>false</is_claimable><name>Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer</name><description>Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and to explore factors associated with efficacy.</description><dates><creation>2018-01-15</creation></dates><accession>2261627</accession><cross_references><ClinicalTrials___gov>NCT03377842</ClinicalTrials___gov></cross_references></HashMap>